Acousia Therapeutics

About

Acousia Therapeutics is a privately held biotech company.

Tübingen,Baden-Wurttemberg,Germany
11 - 50

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: €2.50M
Industries: Biotechnology,Health Care,Therapeutics
Founded date: Jan 1, 2012
Number Of Employee: 11 - 50
Operating Status: Active
Legal Name: Acousia Therapeutics GmbH

Acousia Therapeutics GmbH is a privately held biotech company based in Tübingen, Germany. Acousia has experience and expertise in identifying and developing small molecule drug candidates for the treatment of hearing loss.

Sensory hair cells are the key cells for hearing in the inner ear. Acousia`s approach will help to replace lost hair cells by cellular regeneration originating from supporting cells.

ASpherecousia is developing drugs for local application, which will restore hearing in patients who have lost their hearing ability induced by various reasons, e.g. noise trauma, treatment with ototoxic drugs or sudden deafness. In addition, these therapies will have the potential to treat the age-related decrease in hearing capacity.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

3

€12.50M

Acousia Therapeutics has raised a total of €12.50M in funding over 2 rounds. Their latest funding was raised on May 14, 2018 from a Series B round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
May 14, 2018	Series B	€10M	5	Creathor Ventures	—	Detail
Dec 14, 2016	Series A	€2.50M	3	Boehringer Ingelheim Venture Fund	—	Detail
Jan 1, 2012	Seed	—	—	—	—	Detail